BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (BPMUF) Stock Price, Quote, News & History

SPY764.75 QQQ737.66−0.04%BTC/USD83,837.51+0.25%DIA513.01+0.03%GLD383.78+0.23%TLT78.49+0.33%

BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (BPMUF) Stock Price, Quote, News & History

BPMUFOTCPK

Trade with Public

$77.40

11.9018.17%

At close: Aug 6, 5:00 PM EST

OverviewNews Financials Sentiment Compare

Key Statistics

Open

$77.40

Volume / Avg.

0 / 35.00

Day Range

- - -

52 Wk Range

59.29 - 77.40

Market Cap

P/E Ratio

16.02

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

Recent Basilea Pharmaceutica AG, Allschwil News

Basilea Announces Health Canada Approves ZEVTERA to Treat Bacterial Lung Infections

Basilea Reports Pfizer has Launched Antifungal Cresemba in Taiwan, Triggering Second Milestone Payment Related to Asia-Pacific

Basilea Pharmaceutica Ltd. (OTC: BPMUF) reported today that its license partner, Pfizer Inc. (NYSE:PFE, "Pfizer"))), has launched the antifungal Cresemba® (isavuconazole) in Taiwan. The launch triggered the second milestone payment (USD 0.5 million) related to the Asia-Pacific territory from Pfizer to Basilea.

Charles Gross

Basilea Receives CHF 5M Milestone Payment from Pfizer Related to Marketing Authorization of Antifungal Cresemba in Russia

Basilea Pharmaceutica Ltd. (OTC: BPMUF) announced today that it has received a CHF5million milestone payment from its license partner Pfizer Inc. (NYSE:PFE, "Pfizer"))). The milestone was triggered by the granting of the marketing authorization for the antifungal Cresemba® (isavuconazole) in the Russian Federation.

Charles Gross

Basilea Announces Completion of License Agreement Extension With Pfizer for Antifungal Cresemba for China and Asia Pacific

Benzinga

Pfizer, Basilea to Develop and Commercialize CRESEMBA in China and Asia Pacific Region

Benzinga

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

58.01M

Investing Cash Flow (TTM)

-2.89M

Financing Cash Flow (TTM)

-11.83M

Free Cash Flow (TTM)

55.11M

Capital Expenditure (TTM)

-2.89M

Net Change in Cash (TTM)

43.28M

Valuation Metrics

Enterprise Value

$890.27M

PE Ratio (TTM)

16.02

PE Ratio (FWD)

12.32

PEG Ratio (TTM)

PS Ratio (TTM)

3.55

PB Ratio (TTM)

4.90

Earnings Yield % (TTM)

6.24%

Earnings Yield % (FWD)

8.12%

EV / EBITDA (TTM)

11.69

Price / EBITDA (TTM)

13.85

Price / Free Cash Flow (TTM)

15.92

Book Value / Share

$15.79

Company Debt

Total Debt

$70.64M

LT Debt

$70.64M

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$12.33M

Total Cash

$173.05M

Debt to Equity

0.51

Issuance of Debt (TTM)

-$12.33M

Repayment of Debt (TTM)

-$12.33M

Key Statistics

Open

$77.40

Volume / Avg.

0 / 35.00

Day Range

- - -

52 Wk Range

59.29 - 77.40

Market Cap

P/E Ratio

16.02

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

About

Sector

Health Care

Industry

Biotechnology

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

How do I buy BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (BPMUF) stock?

You can purchase shares of BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (OTCPK:BPMUF) through any online brokerage.

View our list of the best stock brokerages

Who are BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (BPMUF) competitors?

There are no as such competitors for BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG.

What is the forecast, or price target, for BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (BPMUF) stock?

There is no analysis for BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG to provide a consensus price target.

What is the current price for BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (BPMUF)?

The stock price for BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (OTCPK: BPMUF) is $77.4 last updated August 19, 2026 at 11:55 AM EDT.

Does BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (BPMUF) pay a dividend?

There are no upcoming dividends for BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG.

When is BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (OTCPK:BPMUF) reporting earnings?

BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG does not have any upcoming earnings scheduled.

Is BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (BPMUF) going to split?

There is no upcoming split for BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG.

What sector and industry does BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG (BPMUF) operate in?

BASILEA PHARM AG AKT SHS by Basilea Pharmaceutica AG is in the Health Care sector and Biotechnology industry. They are listed on the OTCPK.